Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients (StimobII)

27. januar 2017 opdateret af: AGIR à Dom

Acute and Medium-term Effects of Neuromuscular Electrical Multisite System (Kneehab®) on Cardiovascular Parameters and Induced Muscle Fatigue in Morbidly Obese Patients: Comparison With the Unidirectional Standard Device

The study was designed to test the following hypotheses:

In patients with severe obesity, a multisite electrostimulation session (m-NMES) will induce higher changes in metabolic, inflammatory and cardiovascular parameters and higher increase in muscle strength during stimulated contractions than conventional unidirectional electrostimulation session (c-NMES).

In patients with severe obesity, a six-weeks m-NMES training program will enhance cardiovascular, metabolic and inflammatory parameters.

Studieoversigt

Detaljeret beskrivelse

Background: Physical activity is known to reduce cardiovascular risk as far as even minor change in lifestyle could occur. In obesity, physical activity programs remain challenging due to multifactorial causes related to body mass such as shortness of breath, traumatological pain or psychosocial causes. Although neuromuscular electrical stimulation training is presently ignored in the management of obesity, this technique may be appropriate and useful for muscle deconditioning in these patients. Furthermore, direct effects of electrostimulation training program on vascular function have been previously reported in spinal cord injury and chronic heart disease, suggesting that improvement in cardiovascular function may be expected. While a promising new technique of multisite electrical stimulation (the Kneehab® system) has been recently commercialized, few study have investigated the acute effects of electrostimulation on vascular function and not any study report the effects of electrical stimulation in obese patients.

MAIN OUTCOME OF THE ACUTE PHASE STUDY (1st part):To study the effect of multisite electrical stimulation session (m-NMES) on arterial stiffness as compared to conventional unidirectional electrical stimulation session (c-NMES) in patients with severe obesity. Secondary outcomes of the observational study: 1/ To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as electrically-induced muscle fatigue as compared with c-NMES in patients with morbid obesity. 2/ To study the profile of responders to electrical stimulation according to body composition, 6-minute walking distance, spontaneous physical activity or susceptibility to tolerate electrical stimulation. Response to electrical stimulation will be assessed by an improvement in arterial stiffness after stimulation, if so.

MAIN OUTCOME OF THE INTERVENTIONAL STUDY (2nd part):To study the effect of a multisite electrical stimulation training program (m-NMES) (6 weeks, 30 sessions) on arterial stiffness in patients with severe obesity. Secondary outcomes of the interventional study: To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as muscle strength, body composition, functional capacity (6-minute walking distance) and spontaneous physical activity, after 15 sessions (3 weeks) and after 30 sessions (6 weeks) of training program. Evaluation of the dose-response to m-NMES training in terms of arterial stiffness and functional capacity.

Expected outcomes: Acute change in arterial stiffness and/or endothelial function is expected after one m-NMES session and/or after c-NMES session. M-NMES session is expected to induce higher changes than c-NMES stimulation session on cardiovascular and muscle parameters. Chronic changes in arterial stiffness and/or endothelial function is expected after 6 weeks of m-NMES training.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female, aged over 18 years
  • Morbid obesity (BMI > 35 kg/m²)
  • Not included into exercise training program in the year prior to inclusion- Spontaneous physical activity lower than 160 min wk (i.e. < 30 min/d x 5 d/wk).

Additional Inclusion criteria for the interventional study:

  • Patients with PWV > 9.3 m / s

Exclusion Criteria:

  • Underage- Pregnant or parturient women
  • Persons deprived of their liberty for judicial or administrative reasons, person under a legal protection measure (article L1121-8)
  • Exclusion period in other studies- Person not affiliated to a social security scheme
  • Chronic alcoholism

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: m-NMES first
Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
Andre navne:
  • Kneehab(R) Stimulator
Andet: c-NMES first
Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
Andre navne:
  • Kneehab(R) Stimulator

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Delta arterial stiffness
Tidsramme: Day1 and Day3
Change in carotid-femoral Pulse wave velocity (PWV) after NMES sessions
Day1 and Day3

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Delta pulse arterial tonus (RH-PAT)
Tidsramme: Day1 and Day3
change in pulse arterial tonometry after NMES sessions
Day1 and Day3
NMES-induced muscle fatigue
Tidsramme: Day1 and Day3
change in maximal voluntary contraction after NMES sessions
Day1 and Day3
Delta blood pressure
Tidsramme: Day1 and Day3
changes in systolic and diastolic blood pressures after NMES sessions
Day1 and Day3
Delta plasmatic biomarkers
Tidsramme: Day1 and Day3
changes in inflammatory and metabolic plasmatic biomarkers after NMES sessions
Day1 and Day3
Body composition
Tidsramme: Day1, Day21 and Day 42
Fat-free mass and fat-free mass indexes assessed by impedancemetry
Day1, Day21 and Day 42
Spontaneous physical activity
Tidsramme: Day1 and Day 42
Number of hours per day of physical activity at 1, 2, 3, 4 or 5 metabolic equivalent(METS),Number of step per day,using a 7-days actigraphy
Day1 and Day 42
Maximal voluntary contraction
Tidsramme: Day1, Day21 and Day 42
Quadriceps peak force
Day1, Day21 and Day 42
Walking distance
Tidsramme: Day1 and Day 42
6-minute-walking test
Day1 and Day 42
Arterial stiffness
Tidsramme: Day1, Day21 and Day 42
Pulse wave velocity (PWV) measurements
Day1, Day21 and Day 42
Pulse artery tone (RH-PAT)
Tidsramme: Day1, Day21 and Day 42
Pulse artery tonometry measurement
Day1, Day21 and Day 42
Plasmatic biomarkers
Tidsramme: Day1, Day21 and Day 42
Inflammatory and metabolic biomarkers
Day1, Day21 and Day 42
Blood pressure
Tidsramme: Day1, Day21 and Day 42
Arterial systolic and diastolic blood pressure
Day1, Day21 and Day 42
Response to m-NMES
Tidsramme: Day42
Delta in current intensity during m-NMES between the first to the last session
Day42

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Jean-Louis Pépin, MD, PhD, Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 2013

Primær færdiggørelse (Forventet)

1. november 2017

Studieafslutning (Forventet)

1. december 2017

Datoer for studieregistrering

Først indsendt

15. januar 2013

Først indsendt, der opfyldte QC-kriterier

26. marts 2013

Først opslået (Skøn)

29. marts 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

30. januar 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. januar 2017

Sidst verificeret

1. juli 2016

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 12-AGIR-04

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner